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Mutations in the CLN1 gene that encodes Palmitoyl protein
thioesterase 1 (PPT1) or CLN1, cause Infantile NCL (INCL,
MIM256730). PPT1 removes long fatty acid chains such as
palmitate from modiﬁed cysteine residues of proteins. The data
shown here result from isolated protein complexes from PPT1-
expressing SH-SY5Y stable cells that were subjected to single step
afﬁnity puriﬁcation coupled to mass spectrometry (AP-MS). Prior
to the MS analysis, we utilised a modiﬁed ﬁlter-aided samplecess article under the CC BY license
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E. Scifo et al. / Data in Brief 4 (2015) 207–216208preparation (FASP) protocol. Based on label free quantitative
analysis of the data by SAINT, 23 PPT1 interacting partners (IP)
were identiﬁed. A dense connectivity in PPT1 network was further
revealed by functional coupling and extended network analyses,
linking it to mitochondrial ATP synthesis coupled protein transport
and thioester biosynthetic process. Moreover, the terms: inhibition
of organismal death, movement disorders and concentration of
lipid were predicted to be altered in the PPT1 network. Data
presented here are related to Scifo et al. (J. Proteomics, 123 (2015)
42–53).
& 2015 Elsevier Inc. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).Speciﬁcations tableSubject area Biology, Proteomics, NeuroscienceMore speciﬁc subject
areaNeuronal Ceroid LipofuscinosesType of data Excel Tables (MS data analysis, GO analysis) and ﬁgures
How data was
acquiredMass spectrometry (Q Exactive Hybrid Quadrupole-Orbitrap mass spectrometer, Thermo Scientiﬁc),
SAINT analysis (version exp3.3), Confocal microscopy (Leica SP8 confocal microscope; Wetzlar,
Germany), qPCR (ABI 7500Fast) and Western blot analysisData format Raw, ﬁltered and analyzed
Experimental factors Brief description of any pretreatment of samples
Experimental
featuresN/AData source location N/A
Data accessibility Data is with this articleValue of the data Novel knowledge of the PPT1 interactome in SH-SY5Y cells
 Label-free quantitation of PPT1 IP to determine their relative abundances
 Identiﬁcation of novel PPT1 IP and insight into novel roles of PPT1
 Identiﬁcation of putative PPT1 substrates
 Preliminary dataset for exploring functional relationships in the PPT1 network1. Data, experimental design, materials and methods
In order to determine PPT1 IP, we ﬁrst cloned full length human PPT1 into CTAP-Puro (a
mammalian retroviral based expression vectors) and generated PPT1 expressing SH-SY5Y stable cells
by retroviral infection. We then isolated PPT1 complexes from the stable cells by Single-step Afﬁnity
puriﬁcation, subjected them to ﬁlter-aided sample preparation (FASP) and performed mass
spectrometry analysis on a Q Exactive Hybrid Quadrupole-Orbitrap instrument. Based on label free
quantitation of the MS data by SAINT platform, we identiﬁed 23 PPT1 interacting partners (IP).
1.1. Retroviral production, transduction and generation of stable cell lines
For producing retroviral particles, DNA of retroviral vectors was introduced into HEK 293T cells
[2,3] simultaneously with two packaging plasmids: pCMV-Gag-Pol vector (expresses gag protein and
E. Scifo et al. / Data in Brief 4 (2015) 207–216 209reverse transcriptase of Moloney murine leukemia virus) [4] and pVSV-G (expresses protein G of
vesicular stomatitis virus) [5]. The three plasmids were mixed in proportions of 7.5:5:1, respectively
and introduced into cells using the calcium phosphate method according to the manufacturer’s
protocol (Life Technologies Europe BV). Cell-free virus was harvested two days post transfection,
ﬁltered through 0.45 μm pore size ﬁlter (Millex-HV Filter Unit, Millipore, Ireland Ltd.) and used to
infect low passage (P5-10) SH-SY5Y cells. Cells were grown in DMEM: F12 Ham’s media (1:1),
supplemented with Penicillin (100 mg/ml), Streptomycin (100 mg/ml), Glutamine, non-essential amino
acids (1 ) and 10% FBS (Life Technologies Europe BV), at 37 1C under humidiﬁed atmosphere of 95%
air and 5% CO2. Stable integrants were isolated by puromycin selection with 1.5 mg/ml and conﬁrmed
using immunocytochemistry and Western blot analysis (see Figs. 1 and 2 in [1]). Stably infected cells
were maintained in an undifferentiated state (.80% conﬂuence) and constantly checked for consistent
growth rates and morphological features.Fig. 1. Flow-chart depicting various steps of afﬁnity puriﬁcation and analysis of PPT1 interacting partners.
Human PPT1 Gateways-compatible entry clone was shuttled into pES-CTAP-Puro destination vector [8], to generate
mammalian expression vector used to infect SH-SY5Y cells. Stably expressing clones were isolated by Puromycin selection,
expanded and subjected to single step Protein G afﬁnity puriﬁcation. Following FASP and Lys-C/Trypsin digestion the
corresponding peptides were separated by nano-LC-ESI tandem mass spectrometry and analysed by bioinformatics tools
(Mascot and SAINT, respectively), prior to ﬁltration of known contaminants. High conﬁdence set containing identiﬁed PPT1
interacting proteins underwent Gene Ontology, pathway and functional association terms network analysis to select targets for
further biochemical and functional validation.
Fig. 2. Expression of untagged human PPT1 and PPT1-CTAP-Puro in the stably transfected SH-SY5Y cells.
(A) mRNA expression levels and enzyme activities of wild type human PPT1(CLN1) were assessed in SH-SY5Y, SH-SY5Y-pcDNA3
and SH-SY5Y-PPT1-pcDNA3 cells, respectively. SH-SY5Y cells stably expressing the untagged human PPT1 had a 10 and 4 fold
difference in mRNA expression and enzyme activity, respectively, in comparison to the cells expressing the empty vector.
(B) Western blotting analysis of the SH-SY5Y, SH-SY5Y-pcDNA3 and SH-SY5Y-PPT1-pcDNA3 cells using rabbit polyclonal anti-
PPT1 (HPA021546, Sigma), indicated three faint bands of 32, 35 and 42 kDa detectable after long exposure from the lysates
of not transfected cells only and cells expressing empty vector (arrows). Stronger band(s) running at 32–39 kDa and one at
42 kDa were detected in the human PPT1 expressing stable cells, after longer exposure. Only two weaker bands were
detected from the lysates of the PPT1 expressing cells, and no signal was visible in lanes with SH-SY5Y and SH-SY5Y-pcDNA3
cells after short exposure. (C) Western blot analysis in empty SH-SY5Y, SH-SY5Y-CTAP-Puro and SH-SY5Y-PPT1-CTAP-Puro
stable cells with anti- human PPT1 and anti-Myc antibodies revealed 3 bands at approx. 60, 80 and 100 kDa. Various
glycosylated PPT1 forms have been observed in mouse ﬁbroblasts and primary neurons [18]. Endogenous PPT1 protein is not
detectable with rabbit polyclonal anti-GST-PPT1 [6]. Glyc is used as an abbreviation for glycosylated form of PPT1 (see Scifo
et al. [1]). Uncharacterized- uncharacterized form of PPT1. Equal protein load was assessed with anti-β actin.
(D) Immunodetection with rabbit polyclonal anti-PPT1 (1:500, red) and mouse monoclonal anti-LAMP1 [H4A3] (1:100, green)
in SH-SY5Y-PPT1-CTAP-Puro cells. Nuclei were counter-stained with Hoechst 33342. PPT1 partially co-localises with the
lysosomal marker, LAMP1 with a 47.9% overlap of the co-localisation signal. Images were acquired using a Leica SP8 confocal
microscope (Wetzlar, Germany) and deconvoluted using Huygens Professional (Scientiﬁc Volume imaging). Analysis of co-
localisation was performed with coloc2 plugin in FIJI image analysis software [7].
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SH SY5Y cells were transfected either with the empty vector pcDNA3 (Invitrogen, LT) or with the
vector carrying CLN1 wild-type gene (CLN1 wt). Cells were cultured in DMEM medium supplemented
with 600 μg/ml G-418 to select for clones stably expressing the constructs. qPCR experiments using
inventoried Taqman assay (Applied Biosystems, Life Technologies) were performed to assess the
expression of CLN1 mRNA (Hs00165579_m1); GAPDH (Hs99999905_m1) was used as reference
endogenous gene. cDNAs were ampliﬁed in a ABI 7500Fast real time PCR. Enzymatic activity was
assessed as previously described in materials and methods. For Western Blotting analysis, cells from
the 3 different cell lines were collected and lysed in RIPA buffer. 40 μg of proteins were separated by
SDS-PAGE and further processed for immunoblotting analysis.
1.3. Immunoﬂuorescence microscopy
SH-SY5Y-PPT1-CTAP-Puro stable cells grown on coverslip glasses were ﬁxed after 48 h with ice
cold methanol prior to blocking with PBS containing 0.5% BSA (PBS-B). The cells were incubated
overnight at þ4 1C with primary antibodies: rabbit polyclonal anti-human-PPT1 (1:300) [6], rabbit
polyclonal anti-PPT1 (HPA021546, 1:500; Sigma) and mouse monoclonal anti-LAMP 1 (H4A3, 1:100,
Developmental Studies Hybridoma Bank, Iowa). They were subsequently washed 3 times with PBS-B
and incubated for 1 h at room temperature with secondary antibodies: goat anti-mouse AlexaFluor-
488 and goat anti-rabbit AlexaFluor-568 (Life Technologies Europe BV). The coverslips were washed
3 times with PBS-B and counter-stained with Hoechst 33342 (10 mg/ml) for 10 min (Life Technologies
Europe BV). The coverslips were ﬁnally washed twice with PBS, rinsed with deionized water and
mounted with Moviol/glycerol mounting media supplemented with 2.5% (v/w) DABCO. Images were
acquired using a Leica SP8 confocal microscope (Wetzlar, Germany) and deconvoluted using Huygens
Professional (Scientiﬁc Volume imaging, Hilversum). Analysis of co-localisation was performed with
coloc2 plugin in FIJI image analysis software [7]. Co-localisation was presented as percentage of
Mander’s overlap coefﬁcient.
1.4. Western blotting and antibodies
Protein samples were separated by standard electrophoresis protocols using homogeneous gels
containing 12% polyacrylamide, 0.1% SDS (SDS-PAGE) under reducing conditions or on gradient Bis-
Tris 4–12% NuPAGEs gels in MES SDS running buffer (Novex; Life Technologies, USA) and transferred
to nitrocellulose membranes (Perkin-Elmer Finland Oy, Turku, Finland). Membranes were blocked
with 3% BSA in TBST buffer (0.01 M Tris–HCl, pH 8.0, 0.15 M NaCl, and 0.1% Tween 20) and incubated
with the following primary Abs: rabbit polyclonal anti-human-PPT1 (1:500) [6], rabbit polyclonal
anti-PPT1 (HPA021546, 1:1000) (Sigma-Aldrich Finland Oy); mouse monoclonal anti-VCP [612182]
(1:1000) (BD Transduction LaboratoriesTM); mouse monoclonal anti-ATP5B [clone 3D5AB1] (A21351,
1:1000) (Molecular Probes/Life Technologies Europe BV, Espoo, Finland); rabbit polyclonal anti-DBH
(NBP1-31386, 1:1500) (Novus Biologicals, Cambridge, UK); mouse monoclonal anti-Myc [9E10] (ab32,
1:1500) and mouse monoclonal anti-β-actin [AC15] (A1978, 1:2000) (Sigma-Aldrich Finland Oy). Each
antibody was used according to the manufacturer’s protocols. After extensively washing with TBST,
the primary antibodies were detected by the appropriate horseradish peroxidase-conjugated
secondary antibodies (Bio-Rad Laboratories AB, Sundbyberg, Sweden) and revealed by chemilumi-
nescence coupled to autoradiography.
1.5. Detection of endogenous PPT1 interacting partners in the protein G afﬁnity pulldowns
Monolayer cells were harvested from three 150 mm plates of PPT1-CTAP-Puro or CTAP-Puro
infected SH-SY5Y cells, grown to 80% conﬂuency (1108 cells). Preparation of cytoplasmic extract
from the cells was performed as previously described [8]. A volume of 200 μl packed IgG-Sepharose
6 Fast Flow resin (Amersham Biosciences) was used for batch puriﬁcation of the cytoplasmic extract
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resin for 16 h at 4 1C, washed thrice with 500 μl of 1 TBS-MNGZ (50 mM Tris–HCl pH 7.4, 150 mM
NaCl, 2.5 mM MgCl2, 0.1% NP-40, 10% glycerol). Equal amounts of puriﬁed Protein-G afﬁnity fractions
(20 mg each), from both empty CTAP-Puro and CTAP-PPT1-Puro were loaded onto gradient Bis-Tris
4–12% NuPAGEs gels in MES SDS running buffer (Novex; Life Technologies, USA) and incubated with
respective primary antibodies (anti-ATP5B, anti-DBH, anti-VCP and anti-β-actin; Section 1.4). The load
control was assessed by probing the lysates (10% of the load) with the same primary antibodies.2. Mass spectrometry analysis
2.1. Nano-LC/ESI/MS/MS analysis, data processing and SAINT analysis
Peptide analysis was performed on a Q Exactive Hybrid Quadrupole-Orbitrap mass spectrometer in
positive ion mode for 182 min, with a selected mass range of 300–2000 mass/charge (m/z). For the
survey scan, resolving power was set to 70,000 at m/z 200, maximum ion injection time 120 ms,
dynamic exclusion of the selected precursor ions was set to 40 s, and the automatic gain control target
value was 1.0e6. MS/MS data were acquired using the top 12 most abundant precursor ions with
charge Z2, as determined by the survey scan. These were selected with an isolation window of
1.2m/z and fragmented via higher energy collisional dissociationwith normalized collision energies of
27%. For the MS/MS scans, resolving power was set to 17.500 at m/z 200, maximum ion injection time
60 ms. MS/MS peak lists or spectral data were searched with the Mascot Daemon interface (version
2.2.0; Matrix Science) against the Swiss-Prot 55.1 database, with taxonomy set to Homo sapiens.
Carbamidomethyl-Cys and Met oxidation were used as ﬁxed and variable modiﬁcations, respectively.
Mass tolerance of the precursor ions was set to 7ass to and of fragment ions to 70.1 Da. The peptide
charge was set to 1þ , 2þ , or 3þ , and two missed tryptic cleavage sites were allowed. Only peptides
which were ranked 1 and scored above the identity threshold score set at 99% conﬁdence were
withheld. SAINT analysis was performed as previously described [9,10], except that three biological
replicates were used for the bait (PPT1) and negative control (empty CTAP-Puro vector). Proteins with
an AvgPates were used for the bait (PPT1) and negative contrafter exclusion of contaminants (proteins
that bind non-speciﬁcally to empty pES-CTAP-Puro vector alone, statistical contaminants (〈www.
crapome.org〉) [11] and previously observed TAP contaminants) [12,13].3. Bioinformatic and network analyses
3.1. Bioinformatic analyses and literature mining
Functional annotation of PPT1 IP for Gene Ontology_biological process (GO_BP) was performed by
ClueGO, using the human genome as a background [14]. The following parameter settings were
utilised: kappa Z0.40, 3% threshold, GO levels 7–11 and a minimum of 2 genes per term (Fig. 4 in [1]
and Supplementary Table 3).
Functional associations of PPT1 IP were analysed using FunCoup database v.3.0 (〈http://FunCoup.
sbc.su.se〉). Based on 24 input genes (including PPT1 and PPT1 IP), 65 functionally coupled pairs with a
very high conﬁdence score (40.8, scale 01) were identiﬁed (Fig. 4 and Supplementary Table 5).
3.2. Network analyses
The PPT1 and associated interacting partners were connected using Cytoscape software (〈http://
www.cytoscape.org/〉) (Fig. 5 in Ref [1]) and GeneMania (www.genemania.org (Fig. 3 and
Supplementary Tables 4A–4D) [15,16]. The latter indexes 2,104 association networks containing
535,774,338 interactions mapped to 161,629 genes from 8 organisms, last update 10.07.2014) [17]. The
network was constructed with physical, genetic, predicted and pathway interaction datasets listed by
GeneMania. For weighting of the networks we used GO BP algorithm from GeneMania. Prediction of
Fig. 3. PPT1 interaction network.
PPT1 interaction partners were linked to PPT1 using known physical and genetic interactions, pathway data and utilising
knowledge of predicted interactions. The network was ﬁltered according to GO BP criteria using GeneMANIA algorithm (www.
genemania.org). Overall, 74 nodes of the network could be connected using 88 physical and 69 genetic interactions, 124
pathway and 133 predicted links. Pathway information from Pathway commons (Consolidated-Pathways-2013) was used to
facilitate additional 16 links with varying weights (0.15–16.83%) to the PPT1 network. Nodes enriched with selected GO BP
terms are indicated. Detailed information about the parameters of the network is presented in Supplementary Tables 4A–D.
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Fig. 4. Global network analysis of PPT1 IP.
Functional coupling of PPT1 IP was analysed by FunCoup database v.3.0 (http://FunCoup.sbc.su.se/). Based on 24 input genes
(including PPT1 and PPT1 IP), 65 functionally coupled pairs with a very high conﬁdence score (40.8, scale 01) were
identiﬁed. Dots, dashed and solid lines; indicate scores between (0.82–0.89), (0.9–0.95) and (40.95), respectively. Details are
provided in Supplementary Table 5, Supporting Information.
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(https://analysis.ingenuity.com/). The fold changes derived from spectral counts of SAINT analysis (all
enriched for the PPT1 complex) were utilised as attributes in the analysis (Fig. 5 and Supplementary
Table 5).Appendix A. Supporting information
Supplementary data associated with this article can be found in the online version at http://dx.doi.
org/10.1016/j.dib.2015.05.016.
Fig. 5. PPT1 IP association terms network.
PPT1 interacting partners served as inputs into Ingenuity Pathways analyses (https://analysis.ingenuity.com/). Three terms:
inhibition of organismal death (Z-score 3.109),Movement disorders (Z-score 2.209) and concentration of lipid (Z-score 2.133)
were predicted to be altered in the PPT1 network.
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